Cefuroxime Sodium for Injection

This product has a broad-spectrum antibacterial activity against Gram-positive and Gram-negative bacteria, especially Escherichia coli, Klebsiella, Haemophilus influenzae, Proteus and Bacteroides fragilis. Its mechanism of action is that it shows a strong affinity for penicillin-binding protein, which is the usual point of action of β-lactam antibiotics. It can inhibit cell wall synthesis and bind to peptidoglycan, inhibit the binding of peptidoglycan to lipoprotein to promote bacteriolysis, and show a strong bactericidal effect in a short time. This product shows antibacterial effect in both the bacterial proliferation period and the early stable period, and has a bactericidal effect at concentrations below the MIC, and lyses bacteria in a short time. The antibacterial effect in vivo is stronger than predicted by the MIC. Injection of 200-1600 mg/kg/day of this product has no effect on the reproductive capacity of rat mothers, the development and differentiation of offspring, and the reproductive capacity

Cefuroxime Sodium

This product is white or slightly yellowish white crystalline powder, odorless or with a slight peculiar odor, easily soluble in water, less soluble in methanol, and almost insoluble in ethanol or ether.

This product can be used to treat the following infections caused by the above-mentioned sensitive bacteria: 1 Respiratory system infections: tonsillitis, peritonsillar abscess, bronchitis, bronchiolitis, bronchiectasis (infection), secondary infection of chronic respiratory diseases, pneumonia, pulmonary suppuration. 2 Urinary system infections: pyelonephritis, cystitis. 3 Abdominal infections: cholecystitis, cholangitis, peritonitis. 4 Pelvic infections: pelvic peritonitis, adnexitis, intrauterine infection, pelvic dead cavity inflammation, parametrial tissue inflammation. 5 Sepsis.

This product is only for intravenous injection or intravenous drip. Intravenous injection: During intravenous injection, each lg (titer) of the drug can be dissolved with 20ml of water for injection, 5% glucose injection or 0.9% sodium chloride injection. Intravenous drip: During intravenous drip, each 1g (titer) of the drug can be dissolved with 100-500ml of 5% glucose injection or 0.9% sodium chloride injection, and drip for 1-2 hours. The recommended common dose is: lg (titer) for adults each time, twice a day, which can be increased or decreased appropriately with age and symptoms. For sepsis, refractory or severe infections, it can be increased to 6g (titer) per day, divided into 3-4 doses; children are measured by body weight 20mg (titer)/kg each time, 3-4 times a day.

The following adverse reactions have been observed after this product was marketed: Incidence: Occasionally: less than 0.1%, Sometimes: 0.1-5%, Common: more than 5% or unknown frequency. 1) Serious side effects ① Shock Occasionally shock may occur, so you should pay attention to observation. If discomfort, foreign body sensation in the mouth, wheezing, dizziness, urge to defecate, tinnitus, sweating, etc. occur, the drug should be discontinued and appropriate treatment should be taken. ② Pancytopenia Occasionally pancytopenia may occur, so regular checks should be carried out and observation should be taken. If any abnormality occurs, the drug should be discontinued and appropriate treatment should be taken. ③ Pseudomembranous colitis Occasionally severe colitis such as pseudomembranous colitis accompanied by bloody stools may occur, so pay attention to observation. If abdominal pain or frequent diarrhea occurs, the drug should be discontinued immediately and appropriate treatment should be taken. 2) Observation of similar drugs

It is contraindicated in patients with a history of allergic reactions to cefuroxime or cephem antibiotics.

This product cannot be used in combination with aminophylline or pyridoxal phosphate because it will reduce potency or color. It should not be used in combination with fursultiamine, lipoic acid, hydrocortisone sodium succinate and adenosylcobalamin because it will change color after a while. It should be used as soon as possible after combination. It may increase renal toxicity when used in combination with diuretics (such as furanilamide). Animal experiments have confirmed that this product affects alcohol metabolism, increases blood acetaldehyde concentration, and shows a disulfiram-like effect. Therefore, alcohol should be avoided during or after medication.

Keep in a dark and airtight place in a cool and dry place. Validity period: two years

2.0g (based on C16H21N7O7S3)

STAR Pharmaceutical Pte.ltd

• Founded in:

  1993-08-28

• Address:

  3rd Floor, Office Building, No. 6 Shunda Road, Jiangdong New District, Haikou City, Hainan Province

• Tax NO.:

  91469002620007633W

• Registered Funds:

  HK$50 million

• Website:

  Log in to view

• Email:

  Log in to view